rts logo

Will Esperion Therapeutics Inc. (ESPR) benefit from Wall Street bulls Calls?

Esperion Therapeutics Inc. (NASDAQ: ESPR) is -6.69% lower on its value in year-to-date trading and has touched a low of $0.70 and a high of $3.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ESPR stock was last observed hovering at around $2.68 in the last trading session, with the day’s gains setting it 0.11%.

Currently trading at $2.79, the stock is 20.94% and 17.81% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.53 million and changing 4.10% at the moment leaves the stock 64.62% off its SMA200. ESPR registered 56.74% gain for a year compared to 6-month gain of 191.23%. The firm has a 50-day simple moving average (SMA 50) of $6.02 and a 200-day simple moving average (SMA200) of -$4.66.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The stock witnessed a 11.16% loss in the last 1 month and extending the period to 3 months gives it a -9.42%, and is 21.83% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.24% over the week and 9.77% over the month.

Esperion Therapeutics Inc. (ESPR) has around 240 employees, a market worth around $475.47M and $116.33M in sales. Fwd P/E is 53.50. Profit margin for the company is -179.87%. Distance from 52-week low is 298.57% and -16.34% from its 52-week high. The company has generated returns on investments over the last 12 months (-422.11%).

Esperion Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at $0.05 with sales reaching $84.51M over the same period.The EPS is expected to grow by 80.93% this year, but quarterly earnings will post 127.90% year-over-year. Quarterly sales are estimated to grow 247.40% in year-over-year returns.

Esperion Therapeutics Inc. (ESPR) Top Institutional Holders

161 institutions hold shares in Esperion Therapeutics Inc. (ESPR), with institutional investors hold 42.03% of the company’s shares. The shares outstanding are 170.42M, and float is at 168.54M with Short Float at 10.48%. Institutions hold 41.69% of the Float.

The top institutional shareholder in the company is Wasatch Advisors LP with over 13.14 million shares valued at $18.26 million. The investor’s holdings represent 12.28% of the ESPR Shares outstanding. As of Jun 29, 2023, the second largest holder is Armistice Capital, LLC with 9.19 million shares valued at $12.78 million to account for 8.59% of the shares outstanding. The other top investors are Point72 Asset Management, L.P. which holds 4.97 million shares representing 4.65% and valued at over $6.92 million, while Meditor Group Ltd holds 4.12% of the shares totaling 4.4 million with a market value of $6.12 million.

Esperion Therapeutics Inc. (ESPR) Insider Activity

The most recent transaction is an insider sale by Warren Eric,the company’sChief Commercial Officer. SEC filings show that Warren Eric sold 742 shares of the company’s common stock on Sep 20 ’23 at a price of $1.25 per share for a total of $924.0. Following the sale, the insider now owns 68318.0 shares.

Esperion Therapeutics Inc. disclosed in a document filed with the SEC on Aug 18 ’23 that Warren Eric (Chief Commercial Officer) sold a total of 243 shares of the company’s common stock. The trade occurred on Aug 18 ’23 and was made at $1.41 per share for $344.0. Following the transaction, the insider now directly holds 69060.0 shares of the ESPR stock.

Still, SEC filings show that on Jul 19 ’23, Warren Eric (Chief Commercial Officer) disposed off 106 shares at an average price of $1.58 for $168.0. The insider now directly holds 69,303 shares of Esperion Therapeutics Inc. (ESPR).

Related Posts